One study demonstrated long-term tumor control after short-term targeted therapy with subsequent anti-PD1 antibody in patients with metastatic melanoma, and T cell tumor infiltration was seen in tumor biopsies within 1 week after BRAF/MEK inhibitors administration while less frequent after 2 weeks on therapy (71), suggesting that the timing of combination with PD-1 blockade can impact patient outcomes. Here, MAP2K7 is linked to metastatic melanoma.